Lantern Pharma (LTRN) News Today $3.14 -0.07 (-2.18%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in TaiwanDecember 10, 2024 | insidermonkey.comLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONICâ„¢ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsDecember 9, 2024 | businesswire.comLantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast CancerDecember 7, 2024 | insidermonkey.comLantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast CancerDecember 7, 2024 | msn.comLantern Pharma Shares Rise After Fast-Track Designation for Cancer TreatmentDecember 4, 2024 | marketwatch.comLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)December 4, 2024 | businesswire.comLantern Pharma doses first patient in LP-300 trial expansion cohortNovember 20, 2024 | markets.businessinsider.comLTRN: Pediatric Rare Cancer in FocusNovember 12, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comLantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...November 9, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comLantern Pharma Advances AI-Driven Cancer TherapiesNovember 8, 2024 | markets.businessinsider.comLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 7, 2024 | businesswire.comStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNovember 5, 2024 | finance.yahoo.comLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETOctober 31, 2024 | businesswire.comLantern Pharma to Host & Participate in Two Public Webinars During OctoberOctober 21, 2024 | finance.yahoo.comLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDAOctober 15, 2024 | finance.yahoo.comLantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...October 9, 2024 | finance.yahoo.comLantern Pharma (NASDAQ:LTRN) Stock, Insider Trading ActivityOctober 9, 2024 | benzinga.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersSeptember 24, 2024 | finance.yahoo.comLantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184September 23, 2024 | marketwatch.comLantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And HepatoblastomaSeptember 23, 2024 | markets.businessinsider.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's CancersSeptember 23, 2024 | tmcnet.comLantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a MillionaireAugust 31, 2024 | msn.comLTRN: Second Quarter ResultsAugust 12, 2024 | msn.comLantern Pharma Inc. (LTRN) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.comLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesAugust 9, 2024 | tmcnet.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024August 8, 2024 | investorplace.comLTRN: Harmonic Clinical UpdateAugust 6, 2024 | msn.comLTRN Aug 2024 2.000 putAugust 5, 2024 | ca.finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Sees Significant Decline in Short InterestLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large drop in short interest in June. As of June 15th, there was short interest totalling 333,500 shares, a drop of 20.6% from the May 31st total of 419,800 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 163,200 shares, the short-interest ratio is presently 2.0 days.June 29, 2024 | marketbeat.comLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284June 12, 2024 | businesswire.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 10,000 SharesMay 29, 2024 | insidertrades.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Sells $62,500.00 in StockLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) major shareholder Aaron G.L. Fletcher sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $6.25, for a total value of $62,500.00. Following the transaction, the insider now owns 59,326 shares of the company's stock, valued at $370,787.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.May 28, 2024 | marketbeat.comThe 3 Best Machine Learning Stocks to Quadruple Your Money by 2035May 23, 2024 | investorplace.comLTRN: Expanding Horizons into AsiaMay 14, 2024 | finance.yahoo.comLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 9, 2024 | businesswire.comOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismMay 6, 2024 | businesswire.comLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETMay 2, 2024 | businesswire.com3 Machine Learning Stocks with the Potential to Make You an Overnight MillionaireMay 1, 2024 | investorplace.comH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)April 25, 2024 | markets.businessinsider.comLantern Pharma (NASDAQ:LTRN) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Lantern Pharma in a research note on Thursday.April 25, 2024 | marketbeat.comLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | finance.yahoo.comLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | businesswire.comLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanApril 22, 2024 | businesswire.comLantern Pharma Inc. (LTRN)April 17, 2024 | finance.yahoo.comLantern Pharma Inc Ordinary SharesApril 13, 2024 | morningstar.comLantern Pharma (NASDAQ:LTRN) Trading Down 13.8%Lantern Pharma (NASDAQ:LTRN) Stock Price Down 13.8%April 12, 2024 | marketbeat.comShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Expands By 191.1%Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 420,900 shares, a growth of 191.1% from the March 15th total of 144,600 shares. Based on an average daily volume of 276,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 5.3% of the shares of the stock are sold short.April 12, 2024 | marketbeat.comLantern Pharma Inc (LTRN)April 10, 2024 | investing.com Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼0.000.60▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼01▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADAP News PBYI News ELUT News TIL News BDTX News GALT News MNPR News CGEN News TELO News ATOS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LTRN Stock Alerts